Predictors of Acute Transfer and Mortality Within 6 Months From Admission to an Inpatient Rehabilitation Facility for Patients With Brain Tumors

Published:November 08, 2021DOI:



      To obtain useful information for clinicians in evaluating patients with brain tumors for transfer to and subsequent care in inpatient rehabilitation facilities (IRFs).


      Retrospective chart review.


      Inpatient rehabilitation facility.


      A total of 208 adults with either initial or recurrent brain tumors who were admitted to an IRF between January 2017 and December 2018 after an acute hospitalization.



      Main Outcome Measures

      Transfer from an IRF to an acute care hospital and mortality within 6 months from admission to an IRF.


      Of the 208 patients who met inclusion criteria, 20.2% were transferred to an acute care hospital during the IRF stay, which was associated with prior chemotherapy, steroid use, and laterality of tumor. In total, 36.9% of patients with brain tumors died within 6 months of an IRF admission that was associated with recurrent tumor diagnosis, prior chemotherapy, prior neurosurgical intervention, prior neurostimulant use, use of steroids, isocitrate dehydrogenase and O6-methyl-guanyl-methyl-transferase biomarkers, and laterality and location of tumor.


      Patients with brain tumors have a notable potential for acute hospital transfer and mortality within 6 months of IRF stay, with several tumor- and treatment-related risk factors. This information can help identify functional goals, identify high risk patients, enable closer clinical monitoring, and facilitate focused care discussions at IRFs.


      List of abbreviations:

      AED (antiepileptic drug), IDH (isocitrate dehydrogenase), IRF (inpatient rehabilitation facility), MGMT (O6-methyl-guanyl-methyl-transferase)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Archives of Physical Medicine and Rehabilitation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ostrom QT
        • Cioffi G
        • Gittleman H
        • et al.
        CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016.
        Neuro Oncol. 2019; 21: V1-100
        • Mukand JA
        • Blackinton DD
        • Crincoli MG
        • Lee JJ
        • Santos BB.
        Incidence of neurologic deficits and rehabilitation of patients with brain tumors.
        Am J Phys Med Rehabil. 2001; 80: 346-350
        • Mix JM
        • Granger C V
        • LaMonte MJ
        • et al.
        Characterization of cancer patients in inpatient rehabilitation facilities: a retrospective cohort study.
        Arch Phys Med Rehabil. 2017; 98: 971-980
      1. Centers for Medicare and Medicaid Services. Inpatient Rehabilitation Facilities (IRF) Quality Reporting Program (QRP). Available at: Accessed Febraury 25, 2021.

        • Gallegos-Kearin V
        • Knowlton SE
        • Goldstein R
        • et al.
        Outcome trends of adult cancer patients receiving inpatient rehabilitation.
        Am J Phys Med Rehabil. 2018; 97: 514-522
        • Shin K
        • Guo Y
        • Konzen B
        • Fu J
        • Bruera E.
        Inpatient cancer rehabilitation: the experience of a national comprehensive cancer center.
        Am J Phys Med Rehabil. 2011; 90: S63-S68
        • Guo Y
        • Persyn L
        • Palmer JL
        • Bruera E.
        Incidence of and risk factors for transferring cancer patients from rehabilitation to acute care units.
        Am J Phys Med Rehabil. 2008; 87: 647-653
        • Hoyer EH
        • Needham DM
        • Miller J
        • Deutschendorf A
        • Friedman M
        • Brotman DJ.
        Functional status impairment is associated with unplanned readmissions.
        Arch Phys Med Rehabil. 2013; 94: 1951-1958
        • Asher A
        • Roberts PS
        • Bresee C
        • Zabel G
        • Riggs RV
        • Rogatko A.
        Transferring inpatient rehabilitation facility cancer patients back to acute care (TRIPBAC).
        PM R. 2014; 6: 808-813
        • Leu S
        • von Felten S
        • Frank S
        • et al.
        IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.
        Neuro Oncol. 2013; 15: 469-479
        • Fu JB
        • Parsons HA
        • Shin KY
        • et al.
        Comparison of functional outcomes in low- and high-grade astrocytoma rehabilitation inpatients.
        Am J Phys Med Rehabil. 2010; 89: 205-212
        • Roberts PS
        • Nuño M
        • Sherman D
        • Asher A
        • et al.
        The impact of inpatient rehabilitation on function and survival of newly diagnosed patients with glioblastoma.
        PM R. 2014; 6: 514-521
        • Tang V
        • Rathbone M
        • Park Dorsay J
        • Jiang S
        • Harvey D
        Rehabilitation in primary and metastatic brain tumours: impact of functional outcomes on survival.
        J Neurol. 2008; 255: 820-827
        • Binabaj MM
        • Bahrami A
        • ShahidSales S
        • et al.
        The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials.
        J Cell Physiol. 2018; 233: 378-386
        • Ottenbacher KJ
        • Hsu Y
        • Granger CV
        • Fiedler RC.
        The reliability of the functional independence measure: a quantitative review.
        Arch Phys Med Rehabil. 1996; 77: 1226-1232
        • Reilly JM
        • Gundersen AI
        • Silver JK
        • Tan CO
        • Knowlton SE.
        A comparison of functional outcomes between patients admitted to inpatient rehabilitation after initial diagnosis versus recurrence of glioblastoma multiforme.
        PM R. 2020; 12: 975-983